Cytovia.png
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
13 janv. 2021 07h47 HE | Cytovia Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company focusing on Natural Killer cells in cancer, announced today that it has signed a...
Cytovia.png
Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference
12 nov. 2020 07h30 HE | Cytovia Therapeutics
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in the...
Cytovia.png
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
08 oct. 2020 06h00 HE | Cytovia Therapeutics
NEW YORK and PARIS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement...
Cytovia.png
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020
29 sept. 2020 16h00 HE | Cytovia Therapeutics
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in...
Cytovia.png
CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
07 avr. 2020 09h03 HE | Cytovia Therapeutics
NEW YORK and AUSTIN, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer and...
Cytovia.png
Hebrew University to Collaborate with Cytovia Therapeutics
18 mars 2020 09h00 HE | Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...